Anzeige
Mehr »
Login
Dienstag, 25.02.2020 Börsentäglich über 12.000 News von 619 internationalen Medien
Mega-Chance Palladium: Europäischer Palladiumjunior von der Masse noch völlig unentdeckt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DLU2 ISIN: SE0009414576 Ticker-Symbol: OND 
Frankfurt
24.02.20
16:15 Uhr
11,490 Euro
-1,010
-8,08 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOPEPTIDES AB Chart 1 Jahr
5-Tage-Chart
ONCOPEPTIDES AB 5-Tage-Chart
RealtimeGeldBriefZeit
11,350
11,560
24.02.

Aktuelle News zur ONCOPEPTIDES Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
24.01.Oncopeptides will Host a Webcast on Monday, January 27th at 11.00 (CET)320STOCKHOLM, Jan. 24, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that it will host a webcast at 11am (CET) on Monday, January 27th 2020 where CEO Jakob Lindberg...
► Artikel lesen
ONCOPEPTIDES Aktie jetzt für 4€ handeln
24.01.ONCOPEPTIDES AB: Oncopeptides will host a webcast on Monday, January 27[th] at 11.00 (CET)-
07.01.Oncopeptides Strengthens its Regulatory Function by Appointing Karin Eklund Vanderpol as Head of Regulatory Affairs246STOCKHOLM, Jan. 7, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karin Eklund Vanderpol has been appointed as head of regulatory affairs of Oncopeptides....
► Artikel lesen
07.01.ONCOPEPTIDES AB: Oncopeptides strengthens its regulatory function by appointing Karin Eklund Vanderpol as Head of Regulatory Affairs-
17.12.19Bulletin From the Extraordinary General Meeting in Oncopeptides AB (publ)261STOCKHOLM, Dec. 17, 2019 /PRNewswire/ -- An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm. At the Extraordinary General...
► Artikel lesen
08.12.19Oncopeptides Presents Promising Data from the Phase 2 ANCHOR Combination Study in Patients With RRMM at ASH Annual Meeting 2019439STOCKHOLM, Dec. 8, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH...
► Artikel lesen
08.12.19ONCOPEPTIDES AB: Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 20192
07.12.19Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019694STOCKHOLM, Dec. 7, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting...
► Artikel lesen
07.12.19ONCOPEPTIDES AB: Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019-
06.12.19Oncopeptides Will Host a Webcast on Tuesday, December 10th at 13:00 (CET) to Provide an Update Regarding Data Presented at the ASH Annual Meeting292STOCKHOLM, Dec. 6, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will host a webcast on Tuesday, December 10th, 2019, at 13:00 (CET) to provide...
► Artikel lesen
06.12.19ONCOPEPTIDES AB: Oncopeptides will host a webcast on Tuesday, December 10[th] at 13:00 (CET) to provide an update regarding data presented at the ASH annual meeting-
02.12.19Oncopeptides Appoints Joseph Horvat as President North America186STOCKHOLM, Dec. 2, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Joseph Horvat has been appointed as President North America and CEO of Oncopetides Inc....
► Artikel lesen
02.12.19ONCOPEPTIDES AB: Oncopeptides appoints Joseph Horvat as President North America-
14.11.19Extraordinary General Meeting in Oncopeptides AB (publ)141STOCKHOLM, Nov. 14, 2019 /PRNewswire/ -- The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, ("Oncopeptides" or the...
► Artikel lesen
06.11.19Oncopeptides to Highlight Data From Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019199STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from the clinical program evaluating its lead candidate melflufen in multiple myeloma...
► Artikel lesen
06.11.19ONCOPEPTIDES AB: Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019-
31.10.19Number of Shares and Votes in Oncopeptides227STOCKHOLM, Oct. 31, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise...
► Artikel lesen
31.10.19ONCOPEPTIDES AB: Number of shares and votes in Oncopeptides-
10.10.19Nomination Committee Appointed in Respect of AGM 2020 in Oncopeptides221STOCKHOLM , Oct. 10, 2019 /PRNewswire/ -- According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on May...
► Artikel lesen
10.10.19ONCOPEPTIDES AB: Nomination Committee appointed in respect of AGM 2020 in Oncopeptides-
Seite:  Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1